The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-07-16), Amgen's share price is $299.02. Amgen's Book Value per Share for the quarter that ended in Mar. 2025 was $11.55. Hence, Amgen's PB Ratio of today is 25.90.
The historical rank and industry rank for Amgen's PB Ratio or its related term are showing as below:
AMGN'
s PB Ratio Range Over the Past 10 Years
Min: 3.28 Med: 13.63 Max: 148.84
Current: 25.89
During the past 13 years, Amgen's highest PB Ratio was 148.84. The lowest was 3.28. And the median was 13.63.
AMGN's PB Ratio is ranked worse than 97.51% of 925
companies
in the Drug Manufacturers industry
Industry Median: 2.07
vs AMGN: 25.89
During the past 12 months, Amgen's average Book Value Per Share Growth Rate was 23.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -15.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Amgen was 69.30% per year. The lowest was -26.10% per year. And the median was 13.90% per year.
Back to Basics: PB Ratio
Amgen PB Ratio Historical Data
The historical data trend for Amgen's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amgen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen's PB Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amgen's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Amgen's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Amgen PB Ratio Related Terms
Thank you for viewing the detailed overview of Amgen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 